Mitsubishi Tanabe Ph (MTZXF) 15.7000 $MTZXF
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.64 (-0.23)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 13.80 (-0.28), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 99.62 (+1.18), RVNC: 16.84 (+0.27), CLTX: 6.17 (+0.09), GSK: 47.94 (+1.99), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 16.96 (+0.66), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), NVS: 102.20 (-0.17)
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 60.04 (+0.56)
Rabies Virus Vaccines, Antibodies and Immune Globulins Competitor Analysis
M2 - Tue Oct 21, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2hcln/competitor) has announced the addition of the "Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Rabies virus infections provides a competitor evaluation in the field of marketed and new molecules for prevention or treatment of Rabies virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of therapeutic antibodies, immune globulins and vaccines for prevention and treatment of Rabies virus infections. In addition, the report lists company-specific R&D pipelines of Rabies virus vaccines, antibodies and immune globulins. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Equine Rabies Virus Immune Globulins (ERIG) 2. Human Rabies Virus Immune Globulins (HRIG) 3. Recombinant Rabies Antibodies 4. Rabies Virus Vaccines Companies Mentioned - Bharat Biotech - Bharat Serums & Vaccines - Bio Products Laboratory (BPL) - Cadila Pharmaceuticals - Celltrion - China Biological Products (CBP) - China National Biotec Group (CNBG) - CPL Biologicals (JV of Cadila Pharmaceuticals & Novavax) - CSL (CSL Behring / CSL Biotherapies) - Duraent Biologicals - Grifols - Haffkine Bio-Pharmaceutical Corp. (HBPC) - Humabs Biomed - Indian Immunologicals - Johnson & Johnson (Crucell) - Kamada - Liaoning Cheng Da Biotechnology - Massachusetts Biologics Laboratories (MBL) - Mitsubishi Tanabe Pharma (Medicago) - Molecular Targeting Technologies (MTT) - National Insitute of Allergy and Infectious Diseases (NIAID) - North China Pharmaceutical Group (NCPC) - Novartis - PaxVax - Sanofi Pasteur - Serum Institute of India - Sichuan Yuanda Shuyang Pharmaceutical - The Chemo-Sero Therapeutic Research Institute (Kaketsuken) - Thomas Jefferson University - Wuhan Institute of Biological Products (WIBP) For more information visit http://www.researchandmarkets.com/research/j2hcln/competitor
JNJ: 99.62 (+1.18), NVS: 102.20 (-0.17)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Global Ebola Virus Vaccine Market & Pipeline Insight Report 2014 - Analysis of 26 Clinical Trials & 15 in Preclinical Phase
M2 - Mon Oct 20, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5mpff/ebola_virus) has announced the addition of the "Ebola Virus Vaccine Market & Pipeline Insight" report to their offering. In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment. Ebola Virus Vaccine Market & Pipeline Insight Report Highlight: - Ebola Virus Infection Market Overview - Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Ebola Vaccine in Clinical Trials: 26 Vaccine - Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines - Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status Key Topics Covered: 1. Ebola Virus Infection Market Overview - Symptoms & Diagnostics - Causes of Ebola Virus Infection - Incidence - Ongoing developments - Future Scenario 2. Ebola Vaccine Clinical Trial Overview 3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Research - Preclinical - Clinical - Phase-I 4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - No Development Reported - Discontinued - Suspended 5. Competitive Landscape - Bavarian Nordic - Crucell - Fab Entech - Inovio Pharmaceuticals - Microbiotix - Mitsubishi Tanabe Pharma - Profectus Biosciences - SIGA Technologies - Tekmira Pharmaceuticals - Vaxart For more information visit http://www.researchandmarkets.com/research/h5...bola_virus
INO: 6.80 (-0.15), TKMR: 21.45 (-0.22)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 70.56 (+0.03), ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77)
Global Hyperglycemia Therapeutics Pipeline Review - H2 2014: 3 Companies and 11 Drug Profiles
M2 - Wed Sep 24, 5:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk64nx/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperglycemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kissei Pharmaceutical Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - PhaseBio Pharmaceuticals, Inc. Drug Profiles - PE-0139 - Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - KR-62980 - ZLN-005 - Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - 55-P-0251 - Small Molecules to Inhibit DPP-IV for Hyperglycemia - FGH-10019 - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Small Molecules to Antagonize PST Receptor for Dysglycemic States For more information visit http://www.researchandmarkets.com/research/mk...erglycemia
China Pharmaceutical Guide 2014 - 9th Edition Out Now
M2 - Tue Aug 12, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbjpjg/china) has announced the addition of the "China Pharmaceutical Guide 2014 (9th Edition)" report to their offering. Written by veteran pharma industry executives to help guide international players navigate through thecomplex and turbulent Chinese healthcare business environment, it is the most authoritative reference on China's pharmaceutical and healthcare business. Extensive coverage on China's pharma industry and healthcare sector, structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharma sales, marketing & distribution, trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharma business, and profiles of leading MNC pharma players in China. The 2014 edition has been thoroughly updated with significantly expanded coverage in recent editions on more sub-sectors, outsourcing, clinical practices, regulatory updates on healthcare reform and drug policies, additional case studies, and latest market / health data updated through mid-2014. Key Topics Covered: Part I Overview Of The Chinese Economy And Business Part II The Chinese Pharmaceutical Industry And Market Part III Pharmaceutical Regulatory Framework Part IV Healthcare Provision And Financing Part V Disease And Drug Consumption Patterns Part VI Pharmaceutical Sales, Marketing And Distribution In China Part VII Contemporary Trends, Opportunities And Strategic Considerations Part VIII Market Entry Strategies And Execution Part IX Mini Case Studies Part X Company Profiles: Multinational Pharma Companies In China Companies Mentioned - Abbvie China (Abbott) - Astellas China - AstraZeneca China - Baxter Healthcare China - Bayer Healthcare China - Beaufour Ipsen China - Boehringer Ingelheim China - Bristol-Myers Squibb China - DSM China - Daiichi Sankyo China - Dainippon Sumitomo Pharma China - Eisai China - Eli Lilly China - Fresenius Kabi China - GE Healthcare China - GlaxoSmithKline China - Johnson & Johnson China - Kyowa Hakko Kirin China - Merck KGAA/Merck Serono China - Merck Sharp & Dhome China - Mitsubishi Tanabe Pharma China - Novartis China - Novo Nordisk China - Otsuka China - Pfizer China - Roche China - Sanofi China - Stada China - TEVA China - Takeda China For more information visit http://www.researchandmarkets.com/research/qbjpjg/china
JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), RIGL: 2.47 (+0.05), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.64 (-0.23)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 13.80 (-0.28), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 99.62 (+1.18), RVNC: 16.84 (+0.27), CLTX: 6.17 (+0.09), GSK: 47.94 (+1.99), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 16.96 (+0.66), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), NVS: 102.20 (-0.17)
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 60.04 (+0.56)
Rabies Virus Vaccines, Antibodies and Immune Globulins Competitor Analysis
M2 - Tue Oct 21, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2hcln/competitor) has announced the addition of the "Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Rabies virus infections provides a competitor evaluation in the field of marketed and new molecules for prevention or treatment of Rabies virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of therapeutic antibodies, immune globulins and vaccines for prevention and treatment of Rabies virus infections. In addition, the report lists company-specific R&D pipelines of Rabies virus vaccines, antibodies and immune globulins. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Equine Rabies Virus Immune Globulins (ERIG) 2. Human Rabies Virus Immune Globulins (HRIG) 3. Recombinant Rabies Antibodies 4. Rabies Virus Vaccines Companies Mentioned - Bharat Biotech - Bharat Serums & Vaccines - Bio Products Laboratory (BPL) - Cadila Pharmaceuticals - Celltrion - China Biological Products (CBP) - China National Biotec Group (CNBG) - CPL Biologicals (JV of Cadila Pharmaceuticals & Novavax) - CSL (CSL Behring / CSL Biotherapies) - Duraent Biologicals - Grifols - Haffkine Bio-Pharmaceutical Corp. (HBPC) - Humabs Biomed - Indian Immunologicals - Johnson & Johnson (Crucell) - Kamada - Liaoning Cheng Da Biotechnology - Massachusetts Biologics Laboratories (MBL) - Mitsubishi Tanabe Pharma (Medicago) - Molecular Targeting Technologies (MTT) - National Insitute of Allergy and Infectious Diseases (NIAID) - North China Pharmaceutical Group (NCPC) - Novartis - PaxVax - Sanofi Pasteur - Serum Institute of India - Sichuan Yuanda Shuyang Pharmaceutical - The Chemo-Sero Therapeutic Research Institute (Kaketsuken) - Thomas Jefferson University - Wuhan Institute of Biological Products (WIBP) For more information visit http://www.researchandmarkets.com/research/j2hcln/competitor
JNJ: 99.62 (+1.18), NVS: 102.20 (-0.17)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Global Ebola Virus Vaccine Market & Pipeline Insight Report 2014 - Analysis of 26 Clinical Trials & 15 in Preclinical Phase
M2 - Mon Oct 20, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5mpff/ebola_virus) has announced the addition of the "Ebola Virus Vaccine Market & Pipeline Insight" report to their offering. In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment. Ebola Virus Vaccine Market & Pipeline Insight Report Highlight: - Ebola Virus Infection Market Overview - Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Ebola Vaccine in Clinical Trials: 26 Vaccine - Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines - Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status Key Topics Covered: 1. Ebola Virus Infection Market Overview - Symptoms & Diagnostics - Causes of Ebola Virus Infection - Incidence - Ongoing developments - Future Scenario 2. Ebola Vaccine Clinical Trial Overview 3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Research - Preclinical - Clinical - Phase-I 4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - No Development Reported - Discontinued - Suspended 5. Competitive Landscape - Bavarian Nordic - Crucell - Fab Entech - Inovio Pharmaceuticals - Microbiotix - Mitsubishi Tanabe Pharma - Profectus Biosciences - SIGA Technologies - Tekmira Pharmaceuticals - Vaxart For more information visit http://www.researchandmarkets.com/research/h5...bola_virus
INO: 6.80 (-0.15), TKMR: 21.45 (-0.22)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 70.56 (+0.03), ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77)
Global Hyperglycemia Therapeutics Pipeline Review - H2 2014: 3 Companies and 11 Drug Profiles
M2 - Wed Sep 24, 5:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk64nx/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperglycemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kissei Pharmaceutical Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - PhaseBio Pharmaceuticals, Inc. Drug Profiles - PE-0139 - Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - KR-62980 - ZLN-005 - Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - 55-P-0251 - Small Molecules to Inhibit DPP-IV for Hyperglycemia - FGH-10019 - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Small Molecules to Antagonize PST Receptor for Dysglycemic States For more information visit http://www.researchandmarkets.com/research/mk...erglycemia
China Pharmaceutical Guide 2014 - 9th Edition Out Now
M2 - Tue Aug 12, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbjpjg/china) has announced the addition of the "China Pharmaceutical Guide 2014 (9th Edition)" report to their offering. Written by veteran pharma industry executives to help guide international players navigate through thecomplex and turbulent Chinese healthcare business environment, it is the most authoritative reference on China's pharmaceutical and healthcare business. Extensive coverage on China's pharma industry and healthcare sector, structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharma sales, marketing & distribution, trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharma business, and profiles of leading MNC pharma players in China. The 2014 edition has been thoroughly updated with significantly expanded coverage in recent editions on more sub-sectors, outsourcing, clinical practices, regulatory updates on healthcare reform and drug policies, additional case studies, and latest market / health data updated through mid-2014. Key Topics Covered: Part I Overview Of The Chinese Economy And Business Part II The Chinese Pharmaceutical Industry And Market Part III Pharmaceutical Regulatory Framework Part IV Healthcare Provision And Financing Part V Disease And Drug Consumption Patterns Part VI Pharmaceutical Sales, Marketing And Distribution In China Part VII Contemporary Trends, Opportunities And Strategic Considerations Part VIII Market Entry Strategies And Execution Part IX Mini Case Studies Part X Company Profiles: Multinational Pharma Companies In China Companies Mentioned - Abbvie China (Abbott) - Astellas China - AstraZeneca China - Baxter Healthcare China - Bayer Healthcare China - Beaufour Ipsen China - Boehringer Ingelheim China - Bristol-Myers Squibb China - DSM China - Daiichi Sankyo China - Dainippon Sumitomo Pharma China - Eisai China - Eli Lilly China - Fresenius Kabi China - GE Healthcare China - GlaxoSmithKline China - Johnson & Johnson China - Kyowa Hakko Kirin China - Merck KGAA/Merck Serono China - Merck Sharp & Dhome China - Mitsubishi Tanabe Pharma China - Novartis China - Novo Nordisk China - Otsuka China - Pfizer China - Roche China - Sanofi China - Stada China - TEVA China - Takeda China For more information visit http://www.researchandmarkets.com/research/qbjpjg/china
JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), RIGL: 2.47 (+0.05), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
